Interim repor - 28 Pages

  1. P. 1

  2. P. 2

  3. P. 3

  4. P. 4

  5. P. 5

  6. P. 6

  7. P. 7

  8. P. 8

  9. P. 9

  10. P. 10

  11. P. 20

Catalogue excerpts

Interim report 2016 1st quarter

 Open the catalogue to page 1

Interim report | 1st quarter 2016 Selected figures Sales and result1) Sales (KEUR) EBITDA (KEUR) EBIT (KEUR) Cash-EBT2) (KEUR) Net result (KEUR) Cash flow and investments3) Operative Cash flow (KEUR) Investing activities in intangible assets (KEUR) Investing activities in tangible assets (KEUR) Total investing activities (KEUR) Value development1) Intangible assets (KEUR) Tangible assets (KEUR) Working Capital (KEUR) Working capital ratio4) (sales) Non-current assets (KEUR) Current assets (KEUR) Capital structure1) Total assets (KEUR) Shareholders’ equity (KEUR) Equity ratio Share5) Total amount...

 Open the catalogue to page 2

Interim report | 1st quarter 2016 Table of Contents Selected Figures Foreword by the Management Board Interim Group Management Report • Business and General Conditions • . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 • Economic Report • Earnings Position Asset Position Financial Position • Risk and Opportunity Report • . . . . . . . . . . . . . . . . . . . . . . . . . . . ....

 Open the catalogue to page 3

Interim report | 1st quarter 2016 Foreword by the Management Board Ladies and Gentlemen, Dear Shareholders, Employees, and Business Partners, The first quarter of 2016 was a very exciting quarter during in the second quarter and an interactive exchange will begin which we managed to achieve major milestones in the imple- with the notified body. mentation of our strategy. In addition, we made further progress in the completion of our With sales of the aap group of EUR 5.1 million in the reporting LOQTEQ® portfolio in the first quarter and, among other things, period and EBITDA of EUR -1.9 million,...

 Open the catalogue to page 4

Interim report | 1st quarter 2016 Our targets set for 2016 include, in particular, the return to the There is still an exciting time ahead of us over the coming nine growth path with planned sales growth for our trauma prod- months in order to achieve the targets set for 2016. We are ucts of 20% with a simultaneous adjustment of the cost struc- confident that we can achieve these targets during this fiscal ture. In addition, a major objective of our further strategic year on the basis of the taken and planned measures. Last but alignment is to unlock the inherent value of our three IP-pro- not least,...

 Open the catalogue to page 5

Interim report | 1st quarter 2016 The Share General information about aap’s share International Securities Identification Number (ISIN) Securities Identification Number (WKN) Listing Stock Symbol Market Segment Prime Sector Capital Stock (03/31/2016) Number of Bearer Shares (03/31/2016) Authorized Capital (03/31/2016) rials GmbH, there was a significant price jump on March 22, 2016, with the quarterly high of EUR 1.67 reached the follow- 506 660 All German stock exchanges, XETRA AAQ Prime Standard (since 16 May 2003) signed share purchase agreement for the sale of aap Biomate- CDAX Prime All Share...

 Open the catalogue to page 6

Interim report | 1st quarter 2016 Analysts‘ Recommendations Research Company Warburg Research GmbH Edison Investment Research GmbH Harald Hof Hans Bostrom Investor Relations Target Price As part of its investor relations work, aap placed great emphaDate sis on continuous and transparent communication with its All research reports by the analysis firms are available at stakeholders also in the first quarter of 2016. Here, the Management Board met and spoke a lot with existing and potential new investors, and held intensive discussions about the equity story and expectations for the current year. www.aap.de/en/investoren/aktie/research....

 Open the catalogue to page 7

Interim report | 1st quarter 2016 Interim Group Management Report Business and General Conditions MAGIC Implants GmbH MAGIC Implants GmbH is a shelf company in which all poten- Organizational and Legal Structure tial development and, if applicable, marketing activities in the In the consolidated financial statements, aap Implantate AG area of magnesium technology should be bundled. The com- and all of its companies have been consolidated using the full pany is based in Berlin. consolidation method, in which the parent company aap Implantate AG directly or indirectly holds the majority of voting rights...

 Open the catalogue to page 8

Interim report | 1st quarter 2016 sented its product portfolio at the annual congress of the Amer- In the magnesium technology area, the primary focus over the ican Academy of Orthopaedic Surgeons (AAOS) in Orlando, reporting period was on analyzing the opportunities to source Florida. The AAOS congress is particularly aimed at orthopaedic various raw materials. aap is also continuing to evaluate vari- surgeons and other healthcare professionals, and alongside its ous opportunities for cooperation with external companies. educational events, it also includes a vast industrial exhibition that is...

 Open the catalogue to page 9

Interim report | 1st quarter 2016 of aap Implantate AG in bone cements, mixing systems and re- Sales in the discontinued operation fell from EUR 4.2 million lated accessories. The closing of the transaction is subject to in the first quarter of 2015 to EUR 2.5 million in the reporting the market standard conditions precedent, which were not met period. This is due to a pure quarterly fluctuation that primarily results from the order behavior of major customers for bone cements and mixing systems. Unless otherwise stated, all remarks regarding the asset, financial and earnings position refer to the...

 Open the catalogue to page 10

Interim report | 1st quarter 2016 amount was realized and higher fees for services to subsidiaries As at the reporting date of March 31, 2016, a total of 177 em- ployees were employed in the continued operation (December 31, 2015: 179 employees). In the discontinued operation, other operating income fell in the first quarter of 2016 from EUR 0.3 million in the same pe- In the discontinued operation, personnel expenses in the first riod in the previous year to EUR 0.1 million, again mainly due quarter of 2016 were unchanged at EUR 0.9 million as com- to one-off income from currency conversion. pared...

 Open the catalogue to page 11

All Aap Implantate catalogues and technical brochures